8-K: Cognition Therapeutics Secures $30M, Advances Alzheimer's Drug

Cognition Therapeutics reported Q3 2025 financial results, secured $30 million in funding, and achieved FDA alignment on a registrational path for its lead Alzheimer's drug, zervimesine.

Summary

• Reported financial results for the third quarter ended September 30, 2025.
• Completed a $30 million registered direct offering of 14,700,000 shares of common stock to institutional investors.
• Achieved alignment with the U.S. FDA on a registrational path for zervimesine (CT1812) in Alzheimer's disease following an end-of-Phase 2 meeting.
• The expanded access program for zervimesine in Dementia with Lewy Bodies (DLB) is ongoing.
• Surpassed 75% enrollment in the Phase 2 START study of zervimesine in early Alzheimer's disease, conducted in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC).
• Executing required clinical pharmacology and bioavailability studies to prepare zervimesine for the next stage of development across indications.
• A proposed registrational Alzheimer's disease study design has been accepted for presentation at the Clinical Trials in Alzheimer's Disease (CTAD) Conference, being held December 1-4, 2025.
• Cash, cash equivalents, and restricted cash equivalents were approximately $39.8 million as of September 30, 2025.
• Total obligated grant funds remaining from the National Institute of Aging (NIA) were $36.3 million.
• Estimates sufficient cash to fund operations and capital expenditures into the second quarter of 2027.
• Research and development expenses were $3.8 million for Q3 2025, a decrease from $11.4 million for the comparable period in 2024, driven by the completion of SHINE and SHIMMER clinical trials.
• General and administrative expenses were $2.6 million for Q3 2025, a decrease from $3.1 million for the comparable period in 2024, primarily due to reduced stock-based compensation expenses.
• Reported a net loss of $4.9 million, or $(0.06) per basic and diluted share, for Q3 2025, compared to a net loss of $9.9 million, or $(0.25) per basic and diluted share, for Q3 2024.

Sentiment

Score: 7

Explanation: The filing presents a generally positive outlook, driven by a successful capital raise, extended cash runway, significant reduction in net loss and operating expenses, and crucial FDA alignment on a registrational path for its lead Alzheimer's drug. The dilution from the offering is a negative, but the strategic progress and financial stability outweigh it for a clinical-stage company.

Positives

• Secured $30 million in new capital through a registered direct offering, strengthening the company's financial position.
• Achieved alignment with the U.S. FDA on a registrational path for zervimesine in Alzheimer's disease, providing a clear regulatory roadmap.
• The FDA demonstrated receptivity to study designs and recruitment strategies that support faster, more cost-effective studies.
• Extended cash runway into the second quarter of 2027, providing financial stability for ongoing operations and clinical development.
• Significant reduction in Research and Development (R&D) expenses to $3.8 million in Q3 2025 from $11.4 million in Q3 2024.
• Reduction in General and Administrative (G&A) expenses to $2.6 million in Q3 2025 from $3.1 million in Q3 2024.
• Net loss significantly improved to $4.9 million in Q3 2025 from $9.9 million in Q3 2024.
• Maintained substantial grant funding with $36.3 million remaining from the National Institute of Aging (NIA).
• Over 75% enrollment achieved in the Phase 2 START study for early Alzheimer's disease.

Negatives

• The $30 million registered direct offering resulted in the issuance of 14,700,000 shares, leading to significant shareholder dilution (weighted-average common shares outstanding increased from 40,418,065 in Q3 2024 to 77,951,513 in Q3 2025).
• The company continues to operate at a net loss, reporting $(4.9) million for Q3 2025.

Risks

• Competition in the neurodegenerative disorder market.
• Ability to secure new and retain existing grant funding.
• Ability to grow and manage growth, maintain relationships with suppliers, and retain management and key employees.
• Ability to successfully advance current and future product candidates through development activities, preclinical studies, and clinical trials, and associated costs.
• Uncertainties inherent in preliminary data, pre-clinical studies, and earlier-stage clinical trials being predictive of results in early or later-stage clinical trials.
• Timing, scope, and likelihood of regulatory filings and approvals, including regulatory approval of product candidates.
• Changes in applicable laws or regulations.
• Potential adverse effects from other economic, business, or competitive factors, including ongoing economic uncertainty.
• Estimates of expenses and profitability may prove inaccurate.
• Evolution of the markets in which the company competes.
• Ability to implement strategic initiatives and continue to innovate existing products.
• Ability to defend intellectual property.
• Impacts of global political changes, global economic conditions, supply chain, and labor force.
• Ability to maintain the listing of common stock on the Nasdaq Capital Market.

Future Outlook

The company anticipates that the ongoing clinical pharmacology and bioavailability studies will support all planned registrational programs for zervimesine. Management was encouraged by the FDA's receptivity to study designs and recruitment strategies that support faster, more cost-effective studies. The company estimates it has sufficient cash to fund operations and capital expenditures into the second quarter of 2027.

Management Comments

• "The $30 million registered direct offering enables us to begin preparations for the next stage of development for zervimesine (CT1812)."
• "The alignment we achieved with the FDA on a registrational path in Alzheimers disease was an important accomplishment."
• "We were encouraged by the agencys receptivity to study designs and recruitment strategies that support faster, more cost-effective studies."
• "Looking ahead, we believe the clinical pharmacology and bioavailability studies we are conducting will support all planned registrational programs for zervimesine."

Industry Context

Cognition Therapeutics operates in the highly competitive and challenging biopharmaceutical sector focused on neurodegenerative disorders, particularly Alzheimer's disease and Dementia with Lewy Bodies. The FDA's receptivity to 'faster, more cost-effective studies' for Alzheimer's disease is a notable development, potentially signaling a more streamlined regulatory environment or an acknowledgment of the urgent need for effective treatments in this area. This could benefit other companies in the space by setting a precedent for regulatory flexibility. The company's focus on the sigma-2 receptor mechanism for zervimesine offers a differentiated approach compared to many other candidates targeting amyloid or tau pathways.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking against industry standards.
• Securing $30 million in a registered direct offering and extending the cash runway into Q2 2027 is a positive indicator of investor confidence and financial stability, which is crucial for clinical-stage biotechs facing long and expensive development cycles.
• Achieving FDA alignment on a registrational path for an Alzheimer's drug is a significant milestone, as regulatory pathways in this disease area have historically been complex and fraught with failures, suggesting a potentially clearer and more efficient path forward compared to historical industry challenges.
• The substantial reduction in R&D expenses is primarily due to the completion of specific clinical trials (SHINE and SHIMMER), which is a natural progression in drug development rather than a sustained cost-saving measure across all programs, making direct comparison to industry-wide efficiency gains difficult without more context.

Stakeholder Impact

• Shareholders: Experience significant dilution due to the issuance of 14,700,000 new shares, but benefit from an extended cash runway and a clearer regulatory path for the lead drug, potentially increasing long-term value.
• Patients (future customers): Benefit from the continued development of zervimesine, particularly the progress in Alzheimer's and DLB programs, offering hope for new treatment options.
• Employees: Increased job security and stability due to the extended cash runway and positive clinical/regulatory momentum.
• Creditors/Investors: Improved financial stability and reduced immediate risk due to the capital raise and extended cash runway.

Next Steps

• Continue the expanded access program of zervimesine in Dementia with Lewy Bodies (DLB).
• Continue enrollment in the Phase 2 START study of zervimesine in early Alzheimer's disease.
• Execute required clinical pharmacology and bioavailability studies for zervimesine across indications.
• Present the proposed registrational Alzheimer's disease study design at the Clinical Trials in Alzheimer's Disease (CTAD) Conference (December 1-4, 2025).
• Begin preparations for the next stage of development for zervimesine (CT1812).

Key Dates

Recommendation

While the company has made significant progress with FDA alignment and secured funding, the substantial share dilution from the direct offering is a concern for existing shareholders. The company is still in clinical stages, and while the path forward is clearer, the success of registrational trials is not guaranteed. The extended cash runway provides stability, but the stock remains speculative. A 'hold' recommendation acknowledges the positive developments while recognizing the inherent risks and dilution impact, suggesting investors monitor further clinical trial results and financial performance before making further commitments.

Keywords

Alzheimer's disease, Dementia with Lewy Bodies, neurodegenerative disorders, zervimesine, CT1812, clinical trial, FDA, biopharmaceutical, drug development, Q3 2025, financial results, registered direct offering, NASDAQ: CGTX